Bone Marrow Transplantation News

Factors such as donor age and donor–recipient HLA-match appeared to contribute to long-term survival among patients undergoing unrelated-donor transplantation for hematologic malignancies, according to study results published in Blood.

HemOnc Today’s Chief Medical Editors — Derek Raghavan, MD, PhD, and John Sweetenham, MD — discuss the proliferation of guidelines based on expert opinion rather than high-level data. They also highlight the potential for guidelines to create confusion or anxiety among patients, as well as influence payer decisions.

Douglas Graham, MD, PhD, has been named director of the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta.

The use of peripheral blood stem cells for allogeneic hematopoietic stem cell transplantation in patients with bone marrow failure appeared more common in underdeveloped regions, according to a research letter published in JAMA.

Four oncology leaders have been elected to ASCO’s board of directors.

The inclusion of antihuman T-lymphocyte immune globulin in a myeloablative conditioning regimen for patients with acute leukemia significantly reduced the rate of chronic graft-versus-host disease following allogeneic stem cell transplantation, according to findings from a prospective, randomized phase 3 study.

ORLANDO, Fla. — A depression diagnosis prior to allogeneic hematopoietic stem cell transplantation appeared associated with a greater risk for acute graft-versus-host disease and mortality, according to results from a retrospective study presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — The infusion of allogeneic anti-CD19 chimeric antigen receptor T cells following allogeneic hematopoietic stem cell transplantation induced remissions without causing graft-versus-host disease among patients with B-cell malignancies, according to research presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — Lentiviral hematopoietic stem cell gene therapy with reduced-intensity conditioning produced pan-immunologic correction of T, B and natural killer cells in the bone marrow of older patients with X-linked severe combined immunodeficiency, according to study results presented at the ASH Annual Meeting and Exposition.

Steven T. Rosen, MD, provost and chief scientific officer for City of Hope, received a Lifetime Achievement Award from the Israel Cancer Research Fund.